The promise of TRAIL - Potential and risks of a novel anticancer therapy

Journal of Molecular Medicine

Volumn 85, Issue 9, 2007, Pages 923-935

  Koschny, Ronald ^a,b   Walczak, Henning ^a   Ganten, Tom M ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemotherapeutics; Primary tumor cells; Sensitization; Toxicity; TRAIL induced apoptosis

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOHEXIMIDE; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; I KAPPA B; IRINOTECAN; LEXATUMUMAP; MAPATUMUMAP; METHOTREXATE; MONOCLONAL ANTIBODY; OXALIPLATIN; SN 50; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VALPROIC ACID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; ESTHESIONEUROBLASTOMA; GLIOBLASTOMA; HUMAN; MEDULLOBLASTOMA; MENINGIOMA; PROMYELOCYTIC LEUKEMIA; REVIEW; SOFT TISSUE SARCOMA; THERAPY EFFECT; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 34547819299     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-007-0194-1     Document Type: Review

References (126)

1. Thorburn A (2004) Death receptor-induced cell killing. Cell Signal 16:139-144
2. Kelley SK, Ashkenazi A (2004) Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4:333-339
3. Mayes PA, El-Deiry WS (2006) The complementary roles of the extrinsic and intrinsic apoptotic pathways in promoting the death of cancer cells. Cancer J 12:247-249
4. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682
5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163
6. Walczak H, Krammer PH (2000) The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58-66
7. Sprick MR, Walczak H (2004) The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim Biophys Acta 1644:125-132
8. Roth W, Reed JC (2004) FLIP protein and TRAIL-induced apoptosis. Vitam Horm 67:189-206
9. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN (2005) c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280:14507-14513
10. Xiao C, Yang BF, Asadi N, Beguinot F, Hao C (2002) Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 277:25020-25025
11. Song JH, Bellail A, Tse MC, Yong VW, Hao C (2006) Human astrocytes are resistant to Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. J Neurosci 26:3299-3308
12. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19:1294-1305
13. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393-403
14. Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ et al (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8:1348-1358
15. Wrzesien-Kus A, Smolewski P, Sobczak-Pluta A, Wierzbowska A, Robak T (2004) The inhibitor of apoptosis protein family and its antagonists in acute leukemias. Apoptosis 9:705-715
16. Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG et al (2006) The clinical trail of TRAIL. Eur J Cancer 42:2233-2240
17. Wajant H, Gerspach J, Pfizenmaier K (2005) Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev 16:55-76
18. Wu XX, Ogawa O, Kakehi Y (2004) TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 67:365-383
19. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98:795-804
20. Gazitt Y (1999) TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13:1817-1824
21. Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G et al (2000) Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 111:580-586
22. MacFarlane M, Harper N, Snowden RT, Dyer MJ, Barnett GA, Pringle JH et al (2002) Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21:6809-6818
23. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, Diverio D et al (2005) TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90:612-624
24. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW et al (1997) Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99:618-624
25. Panner A, James CD, Berger MS, Pieper RO (2005) mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25:8809-8823
26. Clayer M, Bouralexis S, Evdokiou A, Hay S, Atkins GJ, Findlay DM (2001) Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: a potential new approach using TRAIL. J Orthop Surg (Hong Kong) 9:19-22
27. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K (2004) TRAIL and its receptors as targets for cancer therapy. Can Sci 95:777-783
28. Secchiero P, Vaccarezza M, Gonelli A, Zauli G (2004) TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr Pharm Des 10:3673-3681
29. Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290:G129-G136
30. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D et al (2006) TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25:7434-7439
31. Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C et al (2002) Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8:3734-3740
32. Jonsson G, Paulie S, Grandien A (2003) High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Res 23:1213-1218
33. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM (2005) Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 11:5188-5194
34. Azuhata T, Scott D, Griffith TS, Miller M, Sandler AD (2006) Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma. J Pediatr Surg 41:1431-1440
35. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690
36. Schneider P (2000) Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol 322:325-345
37. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL et al (2006) Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12:2640-2646
38. Sayers TJ, Murphy WJ (2006) Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 55:76-84
39. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
40. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J et al (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299:31-38
41. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385
42. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR et al (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564-567
43. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954-960
44. Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS (2000) The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 60:6259-6265
45. Ozoren N, El-Deiry WS (2002) Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4:551-557
46. Dunn JC, Tompkins RG, Yarmush ML (1992) Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation. J Cell Biol 116:1043-1053
47. Ballet F, Bouma ME, Wang SR, Amit N, Marais J, Infante R (1984) Isolation, culture and characterization of adult human hepatocytes from surgical liver biopsies. Hepatology 4:849-854
48. Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC et al (2004) TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64:8502-8506
49. Mori E, Thomas M, Motoki K, Nakazawa K, Tahara T, Tomizuka K et al (2004) Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 11:203-207
50. Liang X, Liu Y, Zhang Q, Gao L, Han L, Ma C et al (2007) Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J Immunol 178:503-510
51. Liu YG, Liu SX, Liang XH, Zhang Q, Gao LF, Han LH et al (2007) Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. Biochem Biophys Res Commun 352:329-334
52. Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, Manns MP et al (2005) Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 54:1590-1596
53. Mundt B, Kuhnel F, Zender L, Paul Y, Tillmann H, Trautwein C et al (2003) Involvement of TRAIL and its receptors in viral hepatitis. Faseb J 17:94-96
54. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U et al (2000) Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 356:827-828
55. Dorr J, Roth K, Zurbuchen U, Deisz R, Bechmann I, Lehmann TN et al (2005) Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate. J Neuroimmunol 167:204-209
56. Hao C, Beguinot F, Condorelli G, Trencia A, Van Meir EG, Yong VW et al (2001) Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res 61:1162-1170
57. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH et al (2000) Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 60:553-559
58. Jansen BJ, Van Ruissen F, Cerneus S, Cloin W, Bergers M, Van Erp PE et al (2003) Tumor necrosis factor related apoptosis inducing ligand triggers apoptosis in dividing but not in differentiating human epidermal keratinocytes. J Invest Dermatol 121:1433-1439
59. Qin J, Chaturvedi V, Bonish B, Nickoloff BJ (2001) Avoiding premature apoptosis of normal epidermal cells. Nat Med 7:385-386
60. Qin JZ, Bacon PE, Chaturvedi V, Bonish B, Nickoloff BJ (2002) Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations. Exp Dermatol 11:573-583
61. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E et al (2002) TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 16:67-73
62. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK et al (2004) Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 279:40044-40052
63. Gores GJ, Kaufmann SH (2001) Is TRAIL hepatotoxic? Hepatology 34:3-6
64. Bretz JD, Mezosi E, Giordano TJ, Gauger PG, Thompson NW, Baker JR Jr (2002) Inflammatory cytokine regulation of TRAIL-mediated apoptosis in thyroid epithelial cells. Cell Death Differ 9:274-286
65. Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T et al (2003) TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 171:1061-1069
66. Strater J, Walczak H, Pukrop T, Von Muller L, Hasel C, Kornmann M et al (2002) TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology 122:659-666
67. El-Zawahry A, Lu P, White SJ, Voelkel-Johnson C (2006) In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL. Cancer Gene Ther 13:281-289
68. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W (2004) Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 109:281-290
69. Bremer E, Samplonius D, Kroesen BJ, van Genne L, de Leij L, Helfrich W (2004) Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 6:636-645
70. Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH et al (2005) Target cell-restricted apoptosis induction of acute leukemic t cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 65:3380-3388
71. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF et al (2005) Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 280:10025-10033
72. Assohou-Luty C, Gerspach J, Siegmund D, Muller N, Huard B, Tiegs G et al (2006) A CD40-CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med 84:785-797
73. Buchsbaum DJ, Zhou T, Lobuglio AF (2006) TRAIL receptor-targeted therapy. Future Oncol 2:493-508
74. Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S et al (2003) Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9:3731-3741
75. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE et al (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437-448
76. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS et al (2006) Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12:693-698
77. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C et al (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92:1430-1441
78. Garber K (2005) New apoptosis drugs face critical test. Nat Biotechnol 23:409-411
79. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ (2002) Increased susceptibility to tumor initiation and metastasis in tnf-related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356-1361
80. Sedger LM, Glaccum MB, Schuh JC, Kanaly ST, Williamson E, Kayagaki N et al (2002) Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur J Immunol 32:2246-2254
81. Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H et al (2003) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 63:207-213
82. Wajant H, Pfizenmaier K, Scheurich P (2002) TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7:449-459
83. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ (2006) TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol 84:87-98
84. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K et al (2005) Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42:588-597
85. Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A et al (2007) TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45:649-658
86. Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14:1497-1511
87. Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A et al (2006) Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15:227-230
88. Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M et al (2006) HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 43:425-434
89. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB et al (2005) Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12:773-782
90. Inoue S, MacFarlane M, Harper N, Wheat LM, Dyer MJ, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11(Suppl 2):S193-S206
91. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al (2005) Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11:77-84
92. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T (2004) Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23:6261-6271
93. Chopin V, Slomianny C, Hondermarck H, Le Bourhis X (2004) Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp Cell Res 298:560-573
94. VanOosten RL, Moore JM, Karacay B, Griffith TS (2005) Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression. Cancer Biother 4:1104-1112
95. Singh TR, Shankar S, Srivastava RK (2005) HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24:4609-4623
96. Inoue S, Twiddy D, Dyer MJ, Cohen GM (2006) Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death Differ 13:2160-2162
97. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM (2005) TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65:11265-11270
98. Olsson A, Diaz T, Aguilar-Santelises M, Osterborg A, Celsing F, Jondal M et al (2001) Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D. Leukemia 15:1868-1877
99. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al. (2002) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99:4079-4086
100. Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA (2002) Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62:5800-5806
101. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J et al (2005) The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3:22
102. Jalving M, de Jong S, Koornstra JJ, Boersma-van Ek W, Zwart N, Wesseling J et al (2006) TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res 12:4350-4356
103. Atkins GJ, Bouralexis S, Evdokiou A, Hay S, Labrinidis A, Zannettino AC et al (2002) Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 31:448-456
104. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M et al (2002) Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 99:491-504
105. Van Valen F, Fulda S, Schafer KL, Truckenbrod B, Hotfilder M, Poremba C et al (2003) Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs normal human cells. Int J Cancer 107:929-940
106. Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E et al (2003) Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation. Mol Cell Biol 23:777-790
107. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC et al (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11(Suppl 1):S86-S96
108. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M et al (2005) Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65:4799-4808
109. Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ (2006) Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res 66:9636-9645
110. Schulze-Bergkamen H, Brenner D, Krueger A, Suess D, Fas SC, Frey CR et al (2004) Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology 39:645-654
111. Nguyen DM, Yeow WS, Ziauddin MF, Baras A, Tsai W, Reddy RM et al (2006) The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death. Cancer J 12:257-273
112. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482:193-199
113. Wu XX, Kakehi Y, Mizutani Y, Nishiyama H, Kamoto T, Megumi Y et al (2003) Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 104:409-417
114. Qin JZ, Bacon P, Panella J, Sitailo LA, Denning MF, Nickoloff BJ (2004) Low-dose UV-radiation sensitizes keratinocytes to TRAIL-induced apoptosis. J Cell Physiol 200:155-166
115. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ (1998) Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 161:2833-2840
116. Kothny-Wilkes G, Kulms D, Poppelmann B, Luger TA, Kubin M, Schwarz T (1998) Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 273:29247-29253
117. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ (2003) Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37:87-95
118. Nesterov A, Ivashchenko Y, Kraft AS (2002) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 21:1135-1140
119. Li JH, Kirkiles-Smith NC, McNiff JM, Pober JS (2003) TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 171:1526-1533
120. Griffith TS, Rauch CT, Smolak PJ, Waugh JY, Boiani N, Lynch DH et al (1999) Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 162:2597-2605
121. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Marsters SA, Koeppen H et al (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166:4891-4898
122. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T (2003) Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22:2034-2044
123. Voelkel-Johnson C (2003) An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells. Cancer Biother 2:283-290
124. Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R et al (2005) Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 11:3126-3135
125. Di Pietro R, Secchiero P, Rana R, Gibellini D, Visani G, Bemis K et al (2001) Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 97:2596-2603
126. Wu XX, Kakehi Y, Mizutani Y, Kamoto T, Kinoshita H, Isogawa Y et al (2002) Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Int J Oncol 20:949-954